“With the launch of this Phase 2b trial, we’re moving from possibility to proof - testing not just safety and immunogenicity, but the ShigETEC’s real-world potential”, said Dr. Gábor Somogyi, Chief Executive Officer of Eveliqure.“This Phase 2b study together with the ongoing Phase 1b study with infants, marks a critical step toward a global solution of Shigellosis - not with treatment, but with prevention where it’s needed most”.
“We are proud to be at the forefront of developing a combined broad-spectrum Shigella and ETEC vaccine and honored to collaborate with expert vaccine teams worldwide who share our mission to deliver a long-awaited solution to the global burden of diarrheal diseases.”, commented Dr. Eszter Nagy, Co-Founder and President of Eveliqure.
Read the full press release here